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OBJECTIVES: To assess inﬂuence of HRT with the
pulsed oestrogen therapy, on the women’s quality of life
in the early postmenopausal period. METHODS: Quality
of life (QoL) data were derived from the prospective, clin-
ical, open study carried out in the 16 centres in Poland.
The sample consisted of 102 females at the mean age of
52, reporting climacteric symptoms. QoL was assessed 
at the baseline (V-0), after 12 weeks (V-12) and after 16
weeks (V-16) of active treatment. Two instruments were
used: generic Short Form Health Survey (SF-36) and
median-aged women speciﬁc—Women’s Health Ques-
tionnaire (WHQ). The scoring was processed according
to the questionnaire’s manuals. Statistical signiﬁcance 
of the results obtained in comparison with baseline 
were compared using the Wilcoxon signed—rank test.
RESULTS: Mean value of SF-36 Mental Component
Summary (MCS) was 35.2 ± 10.7 at V-0 and 50.4 ± 8.1
at V-16. Mean value of SF-36 Physical Summary Measure
(PCS) was 46.4 ± 7.8 at V-0 and 52.4 ± 5.5 at V-16. Mean
values for the particular dimensions of the WHQ for V-
0 and respectively for V-16 were as follows: depressed
mood; 0.50 ± 0.26 and 0.89 ± 0.16, somatic symptoms;
0.39 ± 0.25 and 0.84 ± 0.21, memory and concentration;
0.35 ± 0.36 and 0.80 ± 0.28, vasomotor symptoms; 0.08
± 0.23 and 0.96 ± 0.17, anxiety and fears; 0.46 ± 0.28
and 0.90 ± 0.2, sexual behaviour; 0.48 ± 0.38 and 0.69
± 0.34, sleep problems; 0.25 ± 0.31 and 0.87 ± 0.25, men-
strual symptoms; 0.68 ± 0.29 and 0.93 ± 0.15, attrac-
tiveness; 0.46 ± 0.53 and 0.62 ± 0.38. Differences
observed in QoL are statistically signiﬁcant with the p <
0.05. CONCLUSIONS: Pulsed oestrogen therapy
achieved by intranasal oestradiol 300mg has a positive
impact on womens’ general QoL and symptoms related
QoL measured in early postmenopausal period. Improve-
ment is expressed in all of the eight SF-36 scales and in
all of the WHQ dimensions.
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OBJECTIVES: To measure the impact of vasomotor
symptoms on QoL based on a sample of 1655 healthy,
nonhysterectomized, postmenopausal women aged 40 to
65 who were not on hormonal treatment. METHODS:
QoL was assessed with the Women’s Health Question-
naire (WHQ) and the SF-36. Subgroup analyses were
conducted for women with 1) at least 7 moderate to
severe hot ﬂushes per day as reported on daily diary cards
over a 1-week period; 2) at least one but less than 7 mod-
erate to severe hot ﬂushes per day over the same period;
and 3) no hot ﬂushes. RESULTS: Seven percent (7%) of
study participants were in subgroup 1.64% in subgroup
2, and 29% in subgroup 3. Women in subgroup 1 had
signiﬁcantly worse scores (p < 0.05) than women in sub-
group 3 on 8 of 9 WHQ domains (all but attractiveness)
and 4 of 8 SF-36 subscales (vitality, bodily pain, social
function, and role limitations-emotional) and the mental
composite score. Women in subgroup 1 had signiﬁcantly
worse scores (p < 0.05) than women in subgroup 2 on 5
WHQ domains (vasomotor symptoms, sleep problems,
sexual behavior, somatic symptoms and depressed mood)
and 2 SF-36 subscales (vitality and social function).
Women in subgroup 2 had signiﬁcantly worse scores (p <
0.05) than women in subgroup 3 on 5 WHQ domains
(vasomotor symptoms, sleep problems, somatic symp-
toms, memory/concentration, and menstrual symptoms)
and 2 SF-36 subscales (vitality and role limitations-
emotional) and the mental composite score. For each
intergroup comparison, absolute score differences for the
SF-36 were smaller than those for the WHQ, but always
exceeded at least 4 points out of 100 for statistically sig-
niﬁcant differences. CONCLUSIONS: Women with 
moderate to severe hot ﬂushes experience a signiﬁcant
decrease in quality of life as measured by the WHQ and
SF-36. Wyeth Research supported this project.
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OBJECTIVES: Differences in drug effects on the QOL of
patients undergoing assisted reproductive techniques have
been little. The objective of this study was to perform a
QOL analysis using the Short Form-36 combined with
mathematical modeling to determine whether differences
in QOL exist between patients undergoing COS with fol-
litropin alfa (Gonal-FÒ, Serono) and follitropin beta (Fol-
listimÒ/PuregonÒ liquid, Organon). METHODS: The
